Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Laninamivir - Vaxart /Daiichi Sankyo

Drug Profile

Laninamivir - Vaxart /Daiichi Sankyo

Alternative Names: CS-8958; Inavir; LANI; Laninamivir octanoate - Vaxart /Daiichi Sankyo; Laninamivir octanoate hydrate - Vaxart /Daiichi Sankyo; R-118958

Latest Information Update: 25 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Daiichi Sankyo Company; Vaxart
  • Class Acetamides; Antivirals; Carboxylic acids; Esters; Guanidines; Pyrans; Small molecules
  • Mechanism of Action Neuraminidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 13 Feb 2018 Aviragen Therapeutics has merged with Vaxart forming Vaxart
  • 30 Jun 2017 Daiichi Sankyo completes a phase III trial for Influenza virus infections (In neonates, In infants, In children) in Japan (Inhalation) (JapicCTI-163398)
  • 30 Jun 2017 Daiichi Sankyo completes a phase III trial for Influenza virus infections (In children, In adolescents, In adults, In the elderly) in Japan (Inhalation) (JapicCTI-163397)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top